Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
Daxor Corporation (Nasdaq: DXR), the leader in blood volume measurement technology, will showcase its newly FDA-cleared next-generation blood volume analyzer (BVA) at the Heart Failure Society of America Annual Scientific Meeting from September 26-29, 2025.
The new BVA system represents a significant technological advancement, being three times faster than the previous BVA-100™ model, requiring 50% less blood drawn from patients, and maintaining over 95% accuracy with a portable, battery-operated design. New clinical data validating BVA technology will be presented, including research from Wellstar Medical Group and Banner University Medical Center focusing on heart failure patient outcomes.
Daxor Corporation (Nasdaq: DXR), leader nella tecnologia di misurazione del volume di sangue, presenterà il suo nuovo analizzatore di volume sanguigno di prossima generazione, approvato dalla FDA al Heart Failure Society of America Annual Scientific Meeting dal 26 al 29 settembre 2025.
Il nuovo sistema BVA rappresenta un significativo avanzamento tecnologico, essendo tre volte più veloce del precedente modello BVA-100™, richiedendo il 50% in meno di sangue prelevato dai pazienti e mantenendo una precisione superiore al 95% con un design portatile alimentato a batteria. Verranno presentati nuovi dati clinici che convalidano la tecnologia BVA, tra cui ricerche del Wellstar Medical Group e del Banner University Medical Center focalizzate sugli esiti nei pazienti con insufficienza cardiaca.
Daxor Corporation (Nasdaq: DXR), líder en tecnología de medición del volumen de sangre, presentará su nuevo analizador de volumen sanguíneo de próxima generación, aprobado por la FDA en la Reunión Científica Anual de la Heart Failure Society of America del 26 al 29 de septiembre de 2025.
El nuevo sistema BVA representa un avance tecnológico significativo, siendo tres veces más rápido que el modelo BVA-100™ anterior, requiriendo un 50% menos de sangre extraída a los pacientes y manteniendo una precisión superior al 95% con un diseño portátil impulsado por batería. Se presentarán nuevos datos clínicos que validan la tecnología BVA, incluyendo investigaciones del Wellstar Medical Group y del Banner University Medical Center centradas en los resultados de pacientes con insuficiencia cardíaca.
Daxor Corporation (나스닥: DXR), 혈액량 측정 기술의 선두주자로서 산하의 새 FDA 승인 차세대 혈액량 분석기(BVA)를 2025년 9월 26일부터 29일까지 열리는 Heart Failure Society of America 연례 학술대회에서 선보일 예정입니다.
새로운 BVA 시스템은 이전 BVA-100™ 모델보다 세 배 더 빠르고, 환자에서 채취하는 혈액을 50% 줄이며 포터블, 배터리 구동형 디자인으로 95% 이상의 정확도를 유지하는 등 중요한 기술적 진보를 이룹니다. BVA 기술을 검증하는 새로운 임상 데이터가 발표되며, 심부전 환자 결과에 초점을 맞춘 Wellstar Medical Group와 Banner University Medical Center의 연구가 포함됩니다.
Daxor Corporation (Nasdaq: DXR), leader dans la technologie de mesure du volume sanguin, présentera son nouvel analyseur de volume sanguin de prochaine génération, approuvé par la FDA lors de la Heart Failure Society of America Annual Scientific Meeting du 26 au 29 septembre 2025.
Le nouveau système BVA constitue une avancée technologique majeure, étant trois fois plus rapide que le modèle BVA-100™ précédent, nécessitant 50 % de sang en moins prélevé sur les patients et conservant plus de 95 % de précision avec un design portable alimenté par batterie. De nouvelles données cliniques validant la technologie BVA seront présentées, y compris des travaux du Wellstar Medical Group et du Banner University Medical Center axés sur les résultats chez les patients souffrant d’insuffisance cardiaque.
Daxor Corporation (Nasdaq: DXR), der führende Anbieter in der Technologie zur Messung des Blutvolumens, wird seinen neuen FDA-zertifizierten Next-Generation-Blutvolumen-Analyser (BVA) auf der Jahrestagung der Heart Failure Society of America vom 26. bis 29. September 2025 vorstellen.
Das neue BVA-System stellt einen bedeutenden technologischen Fortschritt dar, es ist drei Mal schneller als das vorherige BVA-100™-Modell, es erfordert 50 % weniger Blut von Patienten und bewahrt über 95 % Genauigkeit bei einem tragbaren, batteriebetriebenen Design. Es werden neue klinische Daten zur Validierung der BVA-Technologie präsentiert, einschließlich Studien der Wellstar Medical Group und des Banner University Medical Center, die sich auf Ergebnisse bei Herzinsuffizienz-Patienten konzentrieren.
Daxor Corporation (المدرجة في ناسداك: DXR)، الرائدة في تكنولوجيا قياس حجم الدم، ستعرض جهاز تحليل حجم الدم من الجيل التالي المعتمد من إدارة الغذاء والدواء FDA الجديد في الاجتماع العلمي السنوي لجمعية فشل القلب الأمريكية من 26 إلى 29 سبتمبر 2025.
يعكس نظام BVA الجديد تقدماً تكنولوجياً رئيسياً، فهو أسرع بثلاث مرات من النموذج BVA-100™ السابق، ويتطلب نصف كمية الدم الأقل من المرضى، ويحافظ على أكثر من 95% دقة مع تصميم محمول يعمل بالبطارية. ستُعرض بيانات سريرية جديدة تدعم تقنية BVA، بما في ذلك أبحاث من Wellstar Medical Group وBanner University Medical Center تركز على نتائج مرضى فشل القلب.
Daxor Corporation（纳斯达克股票代码：DXR），血容量测量技术的领导者，将在美国心衰协会年度科学会议上展示其新一代经FDA批准的血容量分析仪（BVA），时间为 2025 年 9 月 26 日至 29 日。
全新的 BVA 系统代表重大技术进步，比上一代 BVA-100™ 快三倍，从患者身上取血量< b>减少 50%，并在便携式、内置电池设计下保持 超过 95% 的准确率。将公布验证 BVA 技术的新临床数据，包括来自 Wellstar Medical Group 与 Banner University Medical Center 的研究，聚焦于心力衰竭患者的结局。
- New BVA system is 3x faster than predecessor
- Device requires 50% less blood drawn from patients
- System maintains over 95% accuracy rate
- FDA clearance received for next-generation analyzer
- Technology targets multi-billion-dollar market opportunity
- None.
Insights
Daxor's next-gen BVA analyzer represents a significant technological advancement that could drive market expansion in the multi-billion-dollar fluid management space.
Daxor's FDA clearance for its next-generation blood volume analyzer (BVA) marks a substantial technological leap in fluid management for heart failure patients. The new device offers three key clinical improvements: it's three times faster than the previous BVA-100™ model, requires 50% less blood draw from patients, and maintains over 95% accuracy from a more portable, battery-operated system.
These advancements directly address critical adoption barriers in clinical settings where efficiency and patient comfort are paramount. By reducing procedural time and invasiveness while maintaining high accuracy, Daxor is positioning its technology to become more accessible in routine heart failure management.
The timing of this unveiling at the HFSA Annual Scientific Meeting is strategically significant, as it places the technology directly before specialists most likely to adopt it. The concurrent presentation of new clinical validation data reinforces the technology's clinical utility, particularly the studies examining outcomes in advanced heart failure patients undergoing LVAD implantation and those with normal intravascular blood volumes.
The company's reference to a "multi-billion-dollar market" signals their recognition of the substantial commercial opportunity in fluid management for heart failure, a condition affecting approximately 6.7 million Americans. By creating a faster, less invasive, and highly portable blood volume measurement system, Daxor appears positioned to potentially capture a larger share of this market than was possible with their previous generation technology.
Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement
OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis, Minnesota, from September 26-29, 2025. The company will debut its newly FDA-cleared, next-generation blood volume analyzer (BVA), signaling a new era of data-driven fluid management for a multi-billion-dollar market.
“The HFSA Annual Scientific Meeting is a premier event that brings together the best scientific minds focused on heart failure science, research, and patient management and the perfect opportunity to unveil Daxor’s latest innovation in fluid management among those practitioners for whom it will be most useful,” said John L. Jefferies, MD, MPH, MBA, Daxor’s CMO. “The recent FDA clearance for our new BVA system is a significant milestone that we are excited to share with the heart failure community, expanding our enhanced clinical potential and market leadership.”
The new analyzer is a significant advancement in the field, designed to unlock widespread adoption of BVA-guided care. The device is three times faster than its predecessor, the BVA-100™, requires
At the meeting, new clinical data that further validates BVA technology from our clinical partners will be also featured in the Exhibit Hall:
- Oral Abstract: ‘A Multi-tiered Approach To Reducing The Incidence Of Renal Replacement Therapy In The Advanced Heart Failure Population Undergoing LVAD Implantation,’ Wellstar Medical Group, Wellstar Health System, Marietta, GA
- e-Poster: ‘Impact Of Normal Intravascular Blood Volumes In Patients With Heart Failure: A Biomarker For Short- and Medium-Term Outcomes,’ Banner University Medical Center, Banner Advanced Heart Failure, Transplant and MCS Program, University of Arizona, Phoenix
“Our new analyzer is a testament to the fact that groundbreaking science can be simplified without sacrificing precision,” said Jonathan Feldschuh, Daxor’s Chief Scientific Officer. “It’s an exciting step toward making this critical data more accessible for clinicians, enabling a new standard of fluid management that will drive significant improvements in heart failure patient outcomes and economic value.”
The company will be participating in Device Day, a focused meeting dedicated to devices in heart failure. We will also be exhibiting at Booth #1007 during the main HFSA meeting.
Learn more here: HFSA ASM 2025.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
For more information, please visit our website at Daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
brets@coreir.com|www.coreir.com
FAQ
What are the key features of Daxor's new blood volume analyzer (BVA)?
When will Daxor (DXR) present its new BVA system at HFSA 2025?
What clinical data will be presented for Daxor's BVA technology at HFSA 2025?
Has Daxor's new blood volume analyzer received FDA clearance?
What is the market opportunity for Daxor's BVA technology?
